Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
- 9 October 2008
- journal article
- clinical trial
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (2), 189-192
- https://doi.org/10.1177/1352458508098268
Abstract
Background Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF). Whereas the ability of rituximab to deplete B cells in peripheral blood and tissue is well known, little information is available about the ability of rituximab to penetrate the barriers separating brain and CSF from the serum compartment. Objective To measure rituximab levels in serum and CSF of rituximab-treated patients and correlate them with CSF and response markers. Methods Fourteen paired serum/CSF samples of patients with autoimmune nervous system disorder were analyzed for up to 43 weeks after rituximab application. Results Rituximab remains detectable within the CSF after i.v. application for up to 24 weeks. Furthermore, levels of rituximab in CSF correlate significantly with the integrity of the blood CSF barrier.Keywords
This publication has 9 references indexed in Scilit:
- Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesisActa Neurologica Scandinavica, 2007
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosisMultiple Sclerosis Journal, 2006
- Pharmacokinetic Behavior of RituximabTherapeutic Drug Monitoring, 2005
- Effective Suppression of Cerebrospinal Fluid B Cells by Rituximab and Cyclophosphamide in Progressive Multiple SclerosisArchives of Neurology, 2005
- Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple SclerosisArchives of Neurology, 2005
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005
- Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?Annals of Oncology, 2000